Abstract
Trimetazidine-based therapy was effective in stable coronary artery disease, with significant improvements from baseline (p<0.05) in: number of angina attacks/week (2.9±2.4 vs 1.1±1.6), angina severity (Canadian Cardiovascular Society Classification 1.9±0.8 vs 1.2±0.8), exercise capacity (metabolic equivalents 6.1±1.7 vs 6.5±1.7), and exercise-induced myocardial ischemia (min 5.5±2.5 vs 6.5±2.6). Trimetazidine treatment significantly (p<0.05) improved glucose metabolism, lowered HbA1c (7.1±1.1% vs 6.6±1.0%), glucose levels (7.7±2.1mmol/l vs 6.9±1.6mmol/l) and decreased arterial stiffness (pulse wave velocity 11.2±2.1m/s vs 10.4±2.2m/s). In most patients, the tolerability of trimetazidine was rated as excellent to good, with a low incidence of adverse events.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
